

## Patient Organisations Disclosure 2024

Novo Nordisk is committed to providing ongoing support for patient organisations in therapeutic areas where we feel we can make a difference. This includes financial and non- financial support in the form of sponsorship of educational meetings, activities and charitable donations.

In 2024, Novo Nordisk supported Diabetes Ireland, European Coalition for People living with Obesity, Global Heart Hub, Irish Coalition for People living with Obesity, Irish Haemophilia Society and Thriveabetes.

In total, the financial value of this support was €241,740 and is detailed in the below table:

PO Name	Country	Types of the Support or Services Provided	Description of the Support or Services	Monetary Value of Financial Support and of Invoiced Costs	Non-Monetary Benefit for PO	Fees for Services Paid
Diabetes Ireland	Ireland	Financial Support	Gold Card Sponsorship	20,000	0	0
Diabetes Ireland	Ireland	Financial Support	Donation	800	0	0
European Coalition for People living with Obesity	Ireland	Financial Support	Training Grants	47,150	0	0
European Coalition for People living with Obesity	Ireland	Financial Support	Obesity Summit	2,184	0	0
European Coalition for People living with Obesity	Ireland	Contracted Services	Consultancy	0	0	1,025
Global Heart Hub	Ireland	Financial Support	Roundtable Sponsorships	86,000	0	0
Global Heart Hub	Ireland	Financial Support	Unite Summit	60,000	0	0
Global Heart Hub	Ireland	Contracted Services	Consultancy	0	0	5,455
Irish Coalition for People living with Obesity	Ireland	Financial Support	Grant	10,900	0	0
Irish Coalition for People living with Obesity	Ireland	Contracted Services	Consultancy	0	0	226
Irish Haemophilia Society	Ireland	Financial Support	Core Funding	7,500	0	0
Thriveabetes	Ireland	Financial Support	Grant	500	0	0

This disclosure was compiled according to the below methodological note.

### Methodological Note

The aim of this Methodology is to provide a clear and simple explanation of how Novo Nordisk Ireland fulfils its reporting obligation and provides a basic framework for interpretation. This Methodology is structured as follows:

1. General Summary
2. Terminology and Definitions showing how Novo Nordisk interprets the disclosure requirements

#### 1. General Summary

Novo Nordisk fully supports the disclosure initiative and puts forth its best effort to implement the transparency initiative. Novo Nordisk Ireland discloses all Novo Nordisk group's support to Patient Organisations (POs) having their Principal Address in Ireland.

## 2. Terminology and Definitions

**Accommodation:** If accommodation is covered by Novo Nordisk, all expenses will be included such as room rate, related taxes etc. Meals and drinks are not subject to disclosure and will not be included.

**Advisory Board:** Support related to Advisory Board activity will be included in the disclosure.

**Cross-Border Payments:** Disclosure of cross-border support is completed by the Novo Nordisk European Federation of Pharmaceutical Industries and Associations (EFPIA) Affiliate where the PO has its Principal Address.

**Disclosure Currency:** Disclosure currency is the local currency of the Novo Nordisk EFPIA Affiliate. i.e. euro. If payments were made in another currency, these have been converted to euro.

**Meals and Drinks:** Meals and drinks are not covered by the EFPIA disclosure requirements and therefore not disclosed.

**Novo Nordisk Organised Events:** Support related to Novo Nordisk company organised events will only be disclosed if these are related to individual travel and accommodation. All other internal or external costs e.g. facilities, conference rooms, joint bus transportation etc. will not be split on the participating individuals and will, therefore, not be disclosed.

**Report Corrections:** Corrections of the this disclosure will be managed by Novo Nordisk on a case-by-case basis.

**Reporting Period:** Disclosure is made on an annual basis, and each reporting period covers a full calendar year (the "Reporting Period"). The Reporting Period is the calendar year 2024 and disclosure is made in June 2025. Tracking of support will follow the payment date and not the date of event. E.g.: An event takes place in November 2023 and the support is paid in February 2024. This will be tracked in 2024 and disclosed in 2025. Payments made under multi-year contracts will also follow the payment date of each individual payment.

**Promotion:** No promotion of Novo Nordisk prescription medicines will take place either directly or indirectly in the course of providing support to Patient Organisations.

This disclosure is made in compliance with Irish Pharmaceutical Healthcare Association Code of Practice for the Pharmaceutical Industry, Annex III: Guideline for Companies on Working with Patient Associations

The Apis bull logo is a registered trademark owned by Novo Nordisk A/S IE25NNG00025, June 2025

